157 related articles for article (PubMed ID: 36974814)
1. Complete Cycles of Radium-223 Improve Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study.
Yang HC; Chang LW; Li JR; Wang SS; Yang CK; Chen CS; Lu K; Chen CC; Wang SC; Lin CY; Cheng CL; Ou YC; Chiu KY; Hung SC
Anticancer Res; 2023 Apr; 43(4):1809-1816. PubMed ID: 36974814
[TBL] [Abstract][Full Text] [Related]
2. Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases.
Yamamoto Y; Okuda Y; Kanaki T; Tanaka R; Nagahara A; Nakai Y; Nakayama M; Kakimoto KI; Nishimura K
Int J Clin Oncol; 2021 Jan; 26(1):192-198. PubMed ID: 32875513
[TBL] [Abstract][Full Text] [Related]
3. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer.
Wong WW; Anderson EM; Mohammadi H; Daniels TB; Schild SE; Keole SR; Choo CR; Tzou KS; Bryce AH; Ho TH; Quevedo FJ; Vora SA
Clin Genitourin Cancer; 2017 Dec; 15(6):e969-e975. PubMed ID: 28545997
[TBL] [Abstract][Full Text] [Related]
4. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
Liu AJ; Kosiorek HE; Ueberroth BE; Jaeger E; Ledet E; Kendi AT; Tzou K; Quevedo F; Choo R; Moore CN; Ho TH; Singh P; Keole SR; Wong WW; Sartor O; Bryce AH
Prostate; 2022 Sep; 82(12):1202-1209. PubMed ID: 35652618
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223.
Al-Ezzi EM; Alqaisi HA; Iafolla MAJ; Wang L; Sridhar SS; Sacher AG; Fallah-Rad N; Jiang DM; Watson GA; Catton CN; Warde PR; Hamilton RJ; Fleshner NE; Zlotta AR; Hansen AR
Cancer Med; 2021 Sep; 10(17):5775-5782. PubMed ID: 34254464
[TBL] [Abstract][Full Text] [Related]
6. Review of Palliative
Arays R; Ahmad Z; Howard L; Veselicky K; Kolodney J; SijinWen ; Hogan T
J Nucl Med Technol; 2021 Mar; 49(1):70-74. PubMed ID: 33219158
[TBL] [Abstract][Full Text] [Related]
7. Impact of pre-treatment variables on the completion of
Lavelli V; Nappi AG; Caputo P; Asabella AN; Fanelli M; Sardaro A; Altini C; Ferrari C; Rubini G
Hell J Nucl Med; 2019; 22 Suppl 2():153-163. PubMed ID: 31802056
[TBL] [Abstract][Full Text] [Related]
8. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
9. Assessing Radiographic Response to
Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
[TBL] [Abstract][Full Text] [Related]
10. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Romero-Laorden N; Lorente D; de Velasco G; Lozano R; Herrera B; Puente J; López PP; Medina A; Almagro E; Gonzalez-Billalabeitia E; Villla-Guzman JC; González-Del-Alba A; Borrega P; Laínez N; Fernández-Freire A; Hernández A; Rodriguez-Vida A; Chirivella I; Fernandez-Parra E; López-Campos F; Isabel Pacheco M; Morales-Barrera R; Fernández O; Villatoro R; Luque R; Hernando S; Castellano DC; Castro E; Olmos D
Eur Urol Oncol; 2024 Jun; 7(3):447-455. PubMed ID: 37838555
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects.
Isaacsson Velho P; Qazi F; Hassan S; Carducci MA; Denmeade SR; Markowski MC; Thorek DL; DeWeese TL; Song DY; Tran PT; Eisenberger MA; Antonarakis ES
Eur Urol; 2019 Aug; 76(2):170-176. PubMed ID: 30293905
[TBL] [Abstract][Full Text] [Related]
12. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
McKay RR; Silver R; Bhak RH; Korves C; Cheng M; Appukkuttan S; Simmons SJ; Duh MS; Taplin ME
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):210-219. PubMed ID: 32814846
[TBL] [Abstract][Full Text] [Related]
14. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway.
Jarvis P; Ho A; Sundram F
Nucl Med Commun; 2021 Mar; 42(3):332-336. PubMed ID: 33252512
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
Armstrong AJ; Gupta S; Healy P; Kemeny G; Leith B; Zalutsky MR; Spritzer C; Davies C; Rothwell C; Ware K; Somarelli JA; Wood K; Ribar T; Giannakakou P; Zhang J; Gerber D; Anand M; Foo WC; Halabi S; Gregory SG; George DJ
PLoS One; 2019; 14(5):e0216934. PubMed ID: 31136607
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen flare induced by
Castello A; Macapinlac HA; Lopci E; Santos EB
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
[TBL] [Abstract][Full Text] [Related]
18. A novel prediction model for the completion of six cycles of radium-223 treatment and survival in patients with metastatic castration-resistant prostate cancer.
Miyoshi Y; Tsutsumi S; Yasui M; Kawahara T; Uemura KI; Hayashi N; Nozawa M; Yoshimura K; Uemura H; Uemura H
World J Urol; 2021 Sep; 39(9):3323-3328. PubMed ID: 33644830
[TBL] [Abstract][Full Text] [Related]
19. A qualitative research study in Japan investigating patients' experience with metastatic castration-resistant prostate cancer: from diagnosis to decision for Ra-223 treatment.
Akakura K; Uemura H; Miyazaki K; Stroupe A; Seo C; Uzumcu A; Ledesma DA
Future Oncol; 2021 Dec; 17(36):5103-5118. PubMed ID: 34664992
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Sartor O; Appukkuttan S; Weiss J; Tsao CK
Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
